Abciximab
Indomethacin may increase the anticoagulant activities of Abciximab.
Abiraterone
The metabolism of Indomethacin can be decreased when combined with Abiraterone.
Acebutolol
Indomethacin may decrease the antihypertensive activities of Acebutolol.
Advertisement
Aceclofenac
The risk or severity of adverse effects can be increased when Indomethacin is combined with Aceclofenac.
Acemetacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Acemetacin.
Acenocoumarol
Indomethacin may increase the anticoagulant activities of Acenocoumarol.
Advertisement
Acetaminophen
The risk or severity of adverse effects can be increased when Indomethacin is combined with Acetaminophen.
Acetyl Sulfisoxazole
The metabolism of Indomethacin can be decreased when combined with Acetyl sulfisoxazole.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Indomethacin.
Advertisement
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Indomethacin.
Alclometasone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Alclometasone.
Aldosterone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.
Aliskiren
Indomethacin may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Indomethacin.
Alprenolol
Indomethacin may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Indomethacin.
Amcinonide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Amcinonide.
Amikacin
Indomethacin may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Indomethacin may decrease the antihypertensive activities of Amiloride.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Aminosalicylic Acid.
Amiodarone
The metabolism of Indomethacin can be decreased when combined with Amiodarone.
Ancrod
Indomethacin may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Indomethacin is combined with Androstenedione.
Anhydrous Tacrolimus
Indomethacin may increase the nephrotoxic activities of Tacrolimus.
Antipyrine
The risk or severity of adverse effects can be increased when Indomethacin is combined with Antipyrine.
Antithrombin III
Indomethacin may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Indomethacin may increase the anticoagulant activities of Antithrombin III human.
Apalutamide
The serum concentration of Indomethacin can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Indomethacin.
Apixaban
Indomethacin may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Indomethacin.
Aprepitant
The metabolism of Indomethacin can be increased when combined with Aprepitant.
Arbekacin
Indomethacin may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Indomethacin may increase the anticoagulant activities of Ardeparin.
Argatroban
Indomethacin may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Indomethacin may increase the anticoagulant activities of Argatroban.
Armodafinil
The metabolism of Indomethacin can be decreased when combined with Armodafinil.
Asenapine
Indomethacin may decrease the antihypertensive activities of Asenapine.
Asian ginseng extract
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ginseng.
Atenolol
Indomethacin may decrease the antihypertensive activities of Atenolol.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Indomethacin.
azficel-T
The risk or severity of adverse effects can be increased when Indomethacin is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indomethacin.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indomethacin.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indomethacin.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Indomethacin.
Balsalazide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Balsalazide.
Bazedoxifene
Indomethacin may increase the thrombogenic activities of Bazedoxifene.
Becaplermin
Indomethacin may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Beclomethasone dipropionate.
Benazepril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indomethacin.
Benzthiazide
The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Indomethacin.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Indomethacin.
Betamethasone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Betamethasone.
Betaxolol
Indomethacin may decrease the antihypertensive activities of Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Indomethacin.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Indomethacin.
Bisoprolol
Indomethacin may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Indomethacin may increase the anticoagulant activities of Bivalirudin.
Bopindolol
Indomethacin may decrease the antihypertensive activities of Bopindolol.
Bortezomib
The metabolism of Indomethacin can be decreased when combined with Bortezomib.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Indomethacin.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Indomethacin.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Indomethacin.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Indomethacin.
Budesonide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Indomethacin is combined with Bufexamac.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Indomethacin.
Bupranolol
Indomethacin may decrease the antihypertensive activities of Bupranolol.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Indomethacin.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Indomethacin.
Capecitabine
The metabolism of Indomethacin can be decreased when combined with Capecitabine.
Capsaicin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Capsaicin.
Captopril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Captopril.
Carbamazepine
The metabolism of Indomethacin can be increased when combined with Carbamazepine.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Indomethacin.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Indomethacin.
Carprofen
The risk or severity of adverse effects can be increased when Indomethacin is combined with Carprofen.
Carteolol
Indomethacin may decrease the antihypertensive activities of Carteolol.
Carvedilol
Indomethacin may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Indomethacin is combined with Celecoxib.
Celiprolol
Indomethacin may decrease the antihypertensive activities of Celiprolol.
Ceritinib
The serum concentration of Indomethacin can be increased when it is combined with Ceritinib.
Certoparin
Indomethacin may increase the anticoagulant activities of Certoparin.
Chloramphenicol
The metabolism of Indomethacin can be decreased when combined with Chloramphenicol.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Indomethacin.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indomethacin.
Chlorotrianisene
Indomethacin may increase the thrombogenic activities of Chlorotrianisene.
Chlorphenesin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Chlorphenesin.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indomethacin.
Cholecalciferol
The metabolism of Indomethacin can be decreased when combined with Cholecalciferol.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Choline magnesium trisalicylate.
Ciclesonide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Cilazapril.
Cilostazol
The serum concentration of Cilostazol can be increased when it is combined with Indomethacin.
Cimetidine
The metabolism of Indomethacin can be decreased when combined with Cimetidine.
Cinoxacin
Indomethacin may increase the neuroexcitatory activities of Cinoxacin.
Ciprofloxacin
Indomethacin may increase the neuroexcitatory activities of Ciprofloxacin.
Cisplatin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Cisplatin.
Citalopram
The metabolism of Indomethacin can be decreased when combined with Citalopram.
Citric Acid
Indomethacin may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Indomethacin may increase the anticoagulant activities of Citric Acid.
Clobetasol
The risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Clodronic Acid.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Indomethacin.
Clotrimazole
The metabolism of Indomethacin can be decreased when combined with Clotrimazole.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Indomethacin.
Colesevelam
Colesevelam can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Cortisone acetate.
Crisaborole
The metabolism of Indomethacin can be decreased when combined with Crisaborole.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Indomethacin.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Indomethacin.
Cyclosporine
Indomethacin may increase the nephrotoxic activities of Cyclosporine.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Indomethacin.
Dabrafenib
The serum concentration of Indomethacin can be decreased when it is combined with Dabrafenib.
Dalteparin
Indomethacin may increase the anticoagulant activities of Dalteparin.
Danaparoid
Indomethacin may increase the anticoagulant activities of Danaparoid.
Deferasirox
The risk or severity of adverse effects can be increased when Indomethacin is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Indomethacin is combined with Deflazacort.
Delavirdine
The metabolism of Indomethacin can be decreased when combined with Delavirdine.
Desipramine
Indomethacin may decrease the antihypertensive activities of Desipramine.
Desirudin
Indomethacin may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Desoxycorticosterone Pivalate.
Desvenlafaxine
Desvenlafaxine may increase the antiplatelet activities of Indomethacin.
Dexamethasone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indomethacin.
Dextran
Indomethacin may increase the anticoagulant activities of Dextran.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Indomethacin.
Dicumarol
Indomethacin may increase the anticoagulant activities of Dicoumarol.
Dienestrol
Indomethacin may increase the thrombogenic activities of Dienestrol.
Diethylstilbestrol
Indomethacin may increase the thrombogenic activities of Diethylstilbestrol.
Diflorasone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Indomethacin is combined with Diflunisal.
Difluprednate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Indomethacin.
Dihydrostreptomycin
Indomethacin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Indomethacin.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Indomethacin.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Indomethacin.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Indomethacin.
Dothiepin
The metabolism of Indomethacin can be decreased when combined with Dosulepin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Indomethacin.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Indomethacin.
Drospirenone
Indomethacin may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Indomethacin is combined with Droxicam.
Duloxetine
Duloxetine may increase the antiplatelet activities of Indomethacin.
Edetic Acid
Indomethacin may increase the anticoagulant activities of Edetic Acid.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Indomethacin.
Efavirenz
The metabolism of Indomethacin can be decreased when combined with Efavirenz.
Eicosapentaenoic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Icosapent.
Enalapril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Indomethacin is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Indomethacin is combined with Enalaprilat.
Enoxacin
Indomethacin may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Indomethacin may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Indomethacin may increase the anticoagulant activities of Enoxaparin.
Eplerenone
Indomethacin may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Indomethacin.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Indomethacin.
Equol, (-)-
Indomethacin may increase the thrombogenic activities of Equol.
Escitalopram
Escitalopram may increase the antiplatelet activities of Indomethacin.
Eslicarbazepine Acetate
The metabolism of Indomethacin can be decreased when combined with Eslicarbazepine acetate.
Esmolol
Indomethacin may decrease the antihypertensive activities of Esmolol.
Esomeprazole
The metabolism of Indomethacin can be decreased when combined with Esomeprazole.
Estradiol
Indomethacin may increase the thrombogenic activities of Estradiol.
Estradiol acetate
Indomethacin may increase the thrombogenic activities of Estradiol acetate.
Estradiol Cypionate
Indomethacin may increase the thrombogenic activities of Estradiol cypionate.
Estradiol Valerate
Indomethacin may increase the thrombogenic activities of Estradiol valerate.
Estriol
Indomethacin may increase the thrombogenic activities of Estriol.
Estrogens, Conjugated (USP)
Indomethacin may increase the thrombogenic activities of Conjugated estrogens.
Estrogens, Esterified (USP)
Indomethacin may increase the thrombogenic activities of Estrogens, esterified.
Estrone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Indomethacin.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indomethacin.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indomethacin.
Ethinyl Estradiol
Indomethacin may increase the thrombogenic activities of Ethinyl Estradiol.
Ethylenediaminetetraacetate
Indomethacin may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Indomethacin is combined with Etodolac.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Indomethacin.
Etoricoxib
The risk or severity of adverse effects can be increased when Indomethacin is combined with Etoricoxib.
Etravirine
The metabolism of Indomethacin can be decreased when combined with Etravirine.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Indomethacin.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Indomethacin.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Indomethacin.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Indomethacin.
Fenoprofen
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fenoprofen.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Indomethacin.
Fish Oils
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fish oil.
Fleroxacin
Indomethacin may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Indomethacin.
Floxuridine
The metabolism of Indomethacin can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Indomethacin can be decreased when combined with Fluconazole.
Fludrocortisone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fludrocortisone.
Fluindione
Indomethacin may increase the anticoagulant activities of Fluindione.
Flumequine
Indomethacin may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Indomethacin is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluorometholone.
Fluorouracil
The metabolism of Indomethacin can be decreased when combined with Fluorouracil.
Fluoxetine
The metabolism of Indomethacin can be decreased when combined with Fluoxetine.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Indomethacin.
Fluticasone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluticasone.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluticasone propionate.
Fluvastatin
The metabolism of Indomethacin can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Indomethacin can be decreased when combined with Fluvoxamine.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Indomethacin.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Indomethacin.
Fondaparinux sodium
Indomethacin may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Indomethacin is combined with Formestane.
Fosinopril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fosinopril.
Fosphenytoin
The metabolism of Indomethacin can be increased when combined with Fosphenytoin.
Framycetin
Indomethacin may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Indomethacin.
Gatifloxacin
Indomethacin may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Indomethacin may increase the neuroexcitatory activities of Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Indomethacin.
Gemfibrozil
The metabolism of Indomethacin can be decreased when combined with Gemfibrozil.
Gemifloxacin
Indomethacin may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Indomethacin may increase the neuroexcitatory activities of Gemifloxacin.
Genistein
Indomethacin may increase the thrombogenic activities of Genistein.
Gentamicin
Indomethacin may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Ginseng Preparation
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ginseng.
Glucagon
The therapeutic efficacy of Glucagon recombinant can be decreased when used in combination with Indomethacin.
glucagon (rDNA)
The therapeutic efficacy of Glucagon recombinant can be decreased when used in combination with Indomethacin.
Grepafloxacin
Indomethacin may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Indomethacin is combined with Haloperidol.
Heparin
Indomethacin may increase the anticoagulant activities of Heparin.
Hydralazine
Indomethacin may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indomethacin.
Hydrocortisone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indomethacin.
Ibandronate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibandronate.
Ibuprofen
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibuprofen.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Indomethacin.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Indomethacin.
Imidapril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Imidapril.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Indomethacin.
Indinavir
The metabolism of Indomethacin can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Indomethacin can be decreased when combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Indomethacin.
Irbesartan
The metabolism of Indomethacin can be decreased when combined with Irbesartan.
Irinotecan
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Indomethacin.
Isavuconazole
The serum concentration of Indomethacin can be increased when it is combined with Isavuconazole.
Isoniazid
The metabolism of Indomethacin can be decreased when combined with Isoniazid.
Kanamycin
Indomethacin may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Indomethacin may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Indomethacin.
Ketoconazole
The metabolism of Indomethacin can be decreased when combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ketoprofen.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Indomethacin.
Korean ginseng preparation
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ginseng.
KOREAN GINSENG ROOT
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ginseng.
Korean Ginseng Root Extract
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ginseng.
Labetalol
Indomethacin may decrease the antihypertensive activities of Labetalol.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Indomethacin.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Indomethacin.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Indomethacin.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Indomethacin.
Lepirudin
Indomethacin may increase the anticoagulant activities of Lepirudin.
Levobetaxolol
Indomethacin may decrease the antihypertensive activities of Levobetaxolol.
Levobunolol
Indomethacin may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Indomethacin may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Indomethacin may increase the neuroexcitatory activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the antiplatelet activities of Indomethacin.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Indomethacin.
Lisinopril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Indomethacin is combined with Lisinopril.
Lithium
The serum concentration of Lithium can be increased when it is combined with Indomethacin.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Indomethacin.
Lomefloxacin
Indomethacin may increase the neuroexcitatory activities of Lomefloxacin.
Lopinavir
The metabolism of Indomethacin can be increased when combined with Lopinavir.
Lornoxicam
The risk or severity of adverse effects can be increased when Indomethacin is combined with Lornoxicam.
Losartan
The metabolism of Indomethacin can be decreased when combined with Losartan.
Loteprednol
The risk or severity of adverse effects can be increased when Indomethacin is combined with Loteprednol.
Lovastatin
The metabolism of Indomethacin can be decreased when combined with Lovastatin.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Indomethacin.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Indomethacin.
Luliconazole
The serum concentration of Indomethacin can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Indomethacin can be decreased when it is combined with Lumacaftor.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Magnesium salicylate.
Manidipine
The metabolism of Indomethacin can be decreased when combined with Manidipine.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Indomethacin.
Meclofenamate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid.
Medronate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Mefenamic acid.
Meloxicam
The risk or severity of adverse effects can be increased when Indomethacin is combined with Meloxicam.
Mepindolol
Indomethacin may decrease the antihypertensive activities of Mepindolol.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Indomethacin.
Mestranol
Indomethacin may increase the thrombogenic activities of Mestranol.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Indomethacin.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indomethacin.
Methylprednisolone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Methylprednisolone.
Metipranolol
Indomethacin may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin.
Metoprolol
Indomethacin may decrease the antihypertensive activities of Metoprolol.
Midostaurin
The metabolism of Indomethacin can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Indomethacin can be increased when it is combined with Mifepristone.
Milnacipran
Milnacipran may increase the antiplatelet activities of Indomethacin.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Indomethacin.
Moclobemide
The metabolism of Indomethacin can be decreased when combined with Moclobemide.
Modafinil
The metabolism of Indomethacin can be decreased when combined with Modafinil.
Moexipril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Indomethacin.
Moxifloxacin
Indomethacin may increase the neuroexcitatory activities of Moxifloxacin.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indomethacin.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Indomethacin.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indomethacin.
Nabilone
The metabolism of Indomethacin can be decreased when combined with Nabilone.
Nabumetone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Nabumetone.
Nadolol
Indomethacin may decrease the antihypertensive activities of Nadolol.
Nadroparin
Indomethacin may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Indomethacin.
Nalidixic Acid
Indomethacin may increase the neuroexcitatory activities of Nalidixic Acid.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Indomethacin.
Naproxen
The risk or severity of adverse effects can be increased when Indomethacin is combined with Naproxen.
Nebivolol
Indomethacin may decrease the antihypertensive activities of Nebivolol.
Nefazodone
Nefazodone may increase the antiplatelet activities of Indomethacin.
Nelfinavir
The metabolism of Indomethacin can be decreased when combined with Nelfinavir.
Neomycin
Indomethacin may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Indomethacin.
Netilmicin
Indomethacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Nicardipine
The metabolism of Indomethacin can be decreased when combined with Nicardipine.
Niflumic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Niflumic Acid.
Nimesulide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Nimesulide.
Norfloxacin
Indomethacin may increase the neuroexcitatory activities of Norfloxacin.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Indomethacin.
Ofloxacin
Indomethacin may increase the neuroexcitatory activities of Ofloxacin.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Indomethacin.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Indomethacin.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Indomethacin.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Indomethacin is combined with Omacetaxine mepesuccinate.
Omeprazole
The metabolism of Indomethacin can be decreased when combined with Omeprazole.
Oxaprozin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaprozin.
Oxprenolol
Indomethacin may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Indomethacin.
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Indomethacin.
Pamidronate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Pamidronate.
Pantoprazole
The metabolism of Indomethacin can be decreased when combined with Pantoprazole.
Paramethasone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Indomethacin is combined with Parecoxib.
Paromomycin
Indomethacin may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Paroxetine
Paroxetine may increase the antiplatelet activities of Indomethacin.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Indomethacin.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Indomethacin.
Pefloxacin
Indomethacin may increase the neuroexcitatory activities of Pefloxacin.
Penbutolol
Indomethacin may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Indomethacin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentosan Polysulfate
Indomethacin may increase the anticoagulant activities of Pentosan Polysulfate.
Perindopril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Perindopril.
Phenindione
Indomethacin may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Indomethacin can be increased when combined with Phenobarbital.
Phenprocoumon
Indomethacin may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Phenylbutazone.
Phenytoin
The metabolism of Indomethacin can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Indomethacin.
Pindolol
Indomethacin may decrease the antihypertensive activities of Pindolol.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Indomethacin.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Indomethacin.
Piroxicam
The risk or severity of adverse effects can be increased when Indomethacin is combined with Piroxicam.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Piroxicam.
Plazomicin
Indomethacin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Polyestradiol Phosphate
Indomethacin may increase the thrombogenic activities of Polyestradiol phosphate.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Indomethacin.
Pomalidomide
The risk or severity of adverse effects can be increased when Indomethacin is combined with Pomalidomide.
Potassium Citrate
Indomethacin may increase the anticoagulant activities of Potassium Citrate.
Practolol
Indomethacin may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Indomethacin.
Prasterone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Prasterone.
Prednicarbate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Pregnenolone.
Primidone
The metabolism of Indomethacin can be increased when combined with Primidone.
Probenecid
The serum concentration of Indomethacin can be increased when it is combined with Probenecid.
Promestriene
Indomethacin may increase the thrombogenic activities of Promestriene.
Propafenone
Indomethacin may decrease the antihypertensive activities of Propafenone.
Propranolol
Indomethacin may decrease the antihypertensive activities of Propranolol.
protein C, human
Indomethacin may increase the anticoagulant activities of Protein C.
protein S, human
Indomethacin may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Indomethacin may increase the anticoagulant activities of Protocatechualdehyde.
Pyrimethamine
The metabolism of Indomethacin can be decreased when combined with Pyrimethamine.
Quinapril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Quinapril.
Quinestrol
Indomethacin may increase the thrombogenic activities of Quinestrol.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Indomethacin.
Quinine
The metabolism of Indomethacin can be decreased when combined with Quinine.
Ramipril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ramipril.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Indomethacin.
Rescinnamine
The risk or severity of adverse effects can be increased when Indomethacin is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Indomethacin is combined with Resveratrol.
Reviparin
Indomethacin may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Indomethacin may increase the anticoagulant activities of Reviparin.
Rifampin
The metabolism of Indomethacin can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Indomethacin can be increased when combined with Rifapentine.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Indomethacin.
Rimexolone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Risedronate.
Rivaroxaban
Indomethacin may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Indomethacin is combined with Rofecoxib.
Rosoxacin
Indomethacin may increase the neuroexcitatory activities of Rosoxacin.
Rucaparib
The metabolism of Indomethacin can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Indomethacin.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Indomethacin.
Salicylic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylic acid.
Salsalate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Salsalate.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Indomethacin.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Indomethacin.
Secobarbital
The metabolism of Indomethacin can be increased when combined with Secobarbital.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Indomethacin.
Sertraline
The metabolism of Indomethacin can be decreased when combined with Sertraline.
Sildenafil
The metabolism of Indomethacin can be decreased when combined with Sildenafil.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Indomethacin.
Sisomicin
Indomethacin may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Citrate
Indomethacin may increase the anticoagulant activities of Sodium Citrate.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Indomethacin.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Indomethacin.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Indomethacin.
Sorafenib
The metabolism of Indomethacin can be decreased when combined with Sorafenib.
Sotalol
Indomethacin may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Indomethacin may increase the neuroexcitatory activities of Sparfloxacin.
Spirapril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Spirapril.
Spironolactone
Indomethacin may decrease the antihypertensive activities of Spironolactone.
Streptomycin
Indomethacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Sulfadiazine
The metabolism of Indomethacin can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Indomethacin can be decreased when combined with Sulfamethoxazole.
Sulfasalazine
The risk or severity of adverse effects can be increased when Indomethacin is combined with Sulfasalazine.
Sulfisoxazole
The metabolism of Indomethacin can be decreased when combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Indomethacin is combined with Sulindac.
Suprofen
The risk or severity of adverse effects can be increased when Indomethacin is combined with Suprofen.
synthetic conjugated estrogens, A
Indomethacin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
Indomethacin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.
Tacrolimus
Indomethacin may increase the nephrotoxic activities of Tacrolimus.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Indomethacin.
Talinolol
Indomethacin may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Indomethacin.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Technetium Tc-99m medronate.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Indomethacin.
Temafloxacin
Indomethacin may increase the neuroexcitatory activities of Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Indomethacin is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Indomethacin is combined with Tenoxicam.
Terbutaline
Indomethacin may decrease the antihypertensive activities of Terbutaline.
Terbutaline Sulfate
Indomethacin may decrease the antihypertensive activities of Terbutaline.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Indomethacin.
Tertatolol
Indomethacin may decrease the antihypertensive activities of Tertatolol.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Tiaprofenic acid.
Tibolone
Indomethacin may increase the thrombogenic activities of Tibolone.
Ticagrelor
The metabolism of Indomethacin can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Indomethacin can be decreased when combined with Ticlopidine.
Tiludronate
The serum concentration of Tiludronic acid can be increased when it is combined with Indomethacin.
Tiludronic Acid
The serum concentration of Tiludronic acid can be increased when it is combined with Indomethacin.
Timolol
Indomethacin may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Indomethacin may decrease the antihypertensive activities of Timolol.
Tixocortol
The risk or severity of adverse effects can be increased when Indomethacin is combined with Tixocortol.
Tobramycin
Indomethacin may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tolbutamide
The metabolism of Indomethacin can be decreased when combined with Tolbutamide.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Indomethacin.
Tolmetin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Tolmetin.
Topiramate
The metabolism of Indomethacin can be decreased when combined with Topiramate.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Indomethacin.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Indomethacin.
Trandolapril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Indomethacin.
Tranylcypromine
The metabolism of Indomethacin can be decreased when combined with Tranylcypromine.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Indomethacin.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Indomethacin.
Triamcinolone
The risk or severity of adverse effects can be increased when Indomethacin is combined with Triamcinolone.
Triamterene
Indomethacin may increase the nephrotoxic activities of Triamterene.
Tribenoside
The risk or severity of adverse effects can be increased when Tribenoside is combined with Indomethacin.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indomethacin.
Trimethoprim
The metabolism of Indomethacin can be decreased when combined with Trimethoprim.
Trisodium Citrate Anhydrous
Indomethacin may increase the anticoagulant activities of Sodium Citrate.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Indomethacin is combined with Trolamine salicylate.
Trovafloxacin
Indomethacin may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Indomethacin may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Indomethacin.
Valdecoxib
The risk or severity of adverse effects can be increased when Indomethacin is combined with Valdecoxib.
Valproate
The metabolism of Indomethacin can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Indomethacin can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Indomethacin can be decreased when combined with Valsartan.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Indomethacin.
Vemurafenib
The serum concentration of Indomethacin can be increased when it is combined with Vemurafenib.
Venlafaxine
Venlafaxine may increase the antiplatelet activities of Indomethacin.
Vincristine
The excretion of Vincristine can be decreased when combined with Indomethacin.
Voriconazole
The metabolism of Indomethacin can be decreased when combined with Voriconazole.
Warfarin
Indomethacin may increase the anticoagulant activities of Warfarin.
Zafirlukast
The metabolism of Indomethacin can be decreased when combined with Zafirlukast.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Indomethacin.
Zofenopril
The risk or severity of adverse effects can be increased when Indomethacin is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Indomethacin is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Indomethacin is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Indomethacin.
